Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed

The Association of the British Pharmaceutical Industry (ABPI) is urging ministers to address excessive levies on manufacturers to ensure the sector remains competitive globally.

The life sciences industry, a key pillar of the UK’s economic strategy, could struggle to attract investment unless payment rates are adjusted.

Last week, the government proposed raising the Statutory Scheme payment rate for newer branded medicines from 15.5% to 32.2% of subject companies’ National Health Service (NHS) sales in the second half of 2025.

The payment rate is the revenue companies must hand back to the government on their sales of branded medicines to the NHS. It is an additional charge to the taxes paid by companies.

Also Read: UK Pharma Industry Trade Association Restores Wegovy/Ozempic Maker Novo Nordisk’s Membership After 2 Years Of Suspension

UK pharmaceutical leaders from Amgen Inc (NASDAQ:AMGN), AstraZeneca Plc (NASDAQ:AZN), Biogen Inc (NASDAQ:BIIB), Boehringer Ingelheim, Bristol Myers Squibb & Co (NYSE:BMY), Daiichi Sankyo ...